Sign in

Private company

Savient Pharmaceuticals

Biopharmaceutical company

Savient Pharmaceuticals was a New Jersey–based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011. It also marketed oxandrolone beginning in 1995.3 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

  • Industrypharmaceutical industry1
  • HeadquartersEast Brunswick1
  • Websitewww.savientpharma.com
  • Listed onNasdaq1
  • Incorporated inDE4
  • Business addressOne Tower Center, East Brunswick, Nj 088164

See how the biggest companies compare on our leaderboards

Savient Pharmaceuticals was a New Jersey–based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011. It also marketed oxandrolone beginning in 1995.3

What it owns

What Savient Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$3.1M6 Dec 31, 2012$3.0M6 Dec 31, 2011+0.9%
Leasehold improvements$3.0M6 Dec 31, 2012$1.5M6 Dec 31, 2011+95.0%
Property and equipment, before depreciation$6.3M6 Dec 31, 2012$4.9M6 Dec 31, 2011+28.3%
Accumulated depreciation$4.3M6 Dec 31, 2012$4.1M6 Dec 31, 2011+4.4%
Property and equipment, net$2.0M6 Dec 31, 2012$833.0K6 Dec 31, 2011+146.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.3M6 Dec 31, 2012$114.1M6 Dec 31, 2011−55.9%
Marketable securities, current$45.9M6 Dec 31, 2012$55.7M6 Dec 31, 2011−17.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$4.3M6 Dec 31, 2012$10.9M6 Dec 31, 2011−60.4%
Raw materials$2.9M6 Dec 31, 2012$3.1M6 Dec 31, 2011−6.3%
Work in process$7.3M6 Dec 31, 2012$10.8M6 Dec 31, 2011−32.3%
Finished goods$1.3M6 Dec 31, 2012$1.6M6 Dec 31, 2011−20.9%

The story

Savient was incorporated in 1980 as Bio-Technology General Corp and changed its name in 2003.

Savient later focused on commercializing pegloticase in the United States and completing the development and seeking regulatory approval in the European Union. The company also sold branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. John H. Johnson was CEO from February 2011 until February 2012, formerly employed by Imclone Systems.

Savient declared bankruptcy in 2013. The drug was selling at $5,390 per vial—around $30,000 for a three-month course of treatment—at the time Savient went under.

Savient was then bought by Crealta. In 2015, Crealta was able to sell the asset to Horizon Pharma for $510 million that year.

From Wikipedia’s article on Savient Pharmaceuticals, shared under CC BY-SA 4.0.5

Leadership

Who has led Savient Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Louis Ferrari2012–2013

President

  1. Paul Hamelin2008–2011
  2. Louis Ferrari2012–2013
  3. David Veitch2013
  4. Philip K. Yachmetz2013

Chief financial officer

  1. Brian J. Hayden2006–2008
  2. David Gionco2009–2011
  3. Kenneth J. Zuerblis2011–2012
2010201520202025
Board members and other officers (26)

Products and brands

  • pegloticase

Listed on Wikidata.1

Former names

  • BIO TECHNOLOGY GENERAL CORPJun 13, 1995 to Jun 6, 20034

Timeline

  1. Jul 11, 2012New chief executive Louis Ferrari becomes CEO7

SEC filer profile

How Savient Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSAVIENT PHARMACEUTICALS INC2
  • CIK0000722104
  • Employer ID (EIN)13-30338112
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
  • Business addressOne Tower Center, East Brunswick, NJ 088162
  • Phone73241893002
  • Shares outstanding73,373,388 as of Nov 11, 201340
  • Public float$38.4M as of Jun 30, 20126
  • On EDGAR sinceApr 13, 19952
  • Filings980 in all: 4 (416), 8-K (167), SC 13G/A (69), 10-Q (56), 4/A (48), SC 13G (33), 3 (25), DEF 14A (19)2
    All 42 form types

    10-K (18), UPLOAD (13), CORRESP (12), 10-Q/A (10), 5 (10), 8-K/A (9), S-8 (9), 10-K/A (8), CT ORDER (7), S-3 (5), SC 13D/A (5), 424B5 (4), DEFA14A (4), SC TO-I/A (4), 8-A12G (3), EFFECT (3), S-3/A (3), 25-NSE (2), NT 10-K (2), NT 10-Q (2), 10-C (1), 3/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-A12G/A (1), ARS (1), DEFR14A (1), FWP (1), POS AM (1), PRE 14A (1), S-3ASR (1), SC 13D (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Apr 1, 2013
    Quarterly report (10-Q) Nov 14, 2013
    Proxy statement (DEF 14A) Apr 30, 2013
    Latest 8-K (8-K) May 30, 2014

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40